EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease

Pascale Gluais Dagorn, Bjoern Buchholz, Andre Kraus, Battsetseg Batchuluun, Hester Bange, Laura Blockken, Gregory R Steinberg, David E Moller, Sophie Hallakou-Bozec

Kidney International · 2023-05 · 103 (5) · 917-929

DOI: 10.1016/j.kint.2023.01.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney International, 2023-05. Verfasst von Pascale Gluais Dagorn und 8 weiteren Autor:innen. Beteiligte Einrichtung: Poxel SA, Lyon, France. Hauptthemen laut MEDLINE: Polycystic Kidney, Autosomal Dominant, Renal Insufficiency, Cysts. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autosomal dominant polycystic kidney disease (ADPKD) mainly results from mutations in the PKD1 gene, which encodes polycystin 1. It is the most common inherited kidney disease and is characterized by a progressive bilateral increase in cyst number and size, often leading to kidney failure. The cellular energy sensor and regulator adenosine monophosphate stimulated protein kinase (AMPK) has been implicated as a promising new therapeutic target. To address this hypothesis, we determined the effects of a potent and selective clinical stage direct allosteric AMPK activator, PXL770, in canine and patient-derived 3D cyst models and an orthologous mouse model of ADPKD. PXL770 induced AMPK activation and dose-dependently reduced cyst growth in principal-like Madin-Darby Canine Kidney cells stimulated with forskolin and kidney epithelial cells derived from patients with ADPKD stimulated with desmopressin. In an inducible, kidney epithelium-specific Pkd1 knockout mouse model, PXL770 produced kidney AMPK pathway engagement, prevented the onset of kidney failure (reducing blood urea by 47%), decreased cystic index by 26% and lowered the kidney weight to body weight ratio by 35% compared to untreated control Pkd1 knockout mice. These effects were accompanied by a reduction of markers of cell proliferation (-48%), macrophage infiltration (-53%) and tissue fibrosis (-37%). Thus, our results show the potential of direct allosteric AMPK activation in the treatment of ADPKD and support the further development of PXL770 for this indication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Kidney, Autosomal DominantRenal InsufficiencyCystsMiceAnimalsDogsAdenosine MonophosphateAMP-Activated Protein KinasesKidneyMice, KnockoutDisease ProgressionTRPP Cation ChannelsPyridonesTetrahydronaphthalenes

Stichwörter der Autor:innen

ADPKDAMPKPXL770fibrosisinflammationmitochondria

Substanzen

Adenosine MonophosphateAMP-Activated Protein KinasesTRPP Cation Channels2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo-5-phenyl-7H-thieno)(2,3-b)pyridin-4-olate potassiumPyridonesTetrahydronaphthalenes

Autor:innen und Institutionen

  • Poxel SA, Lyon, France.
  • Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine and Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
  • Crown Bioscience Netherlands B.V., The Netherlands.
  • InnoSer België NV, Belgium.
  • Poxel SA, Lyon, France. Electronic address: sophie.bozec@poxelpharma.com.

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Dagorn, P. G., Buchholz, B., Kraus, A., Batchuluun, B., Bange, H., Blockken, L., Steinberg, G. R., Moller, D. E., & Hallakou-Bozec, S. (2023). A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease. Kidney International, 103(5), 917-929. https://doi.org/10.1016/j.kint.2023.01.026

Vancouver

Dagorn PG, Buchholz B, Kraus A, Batchuluun B, Bange H, Blockken L, et al. A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease. Kidney International. 2023;103(5):917-929. doi:10.1016/j.kint.2023.01.026

BibTeX
@article{Dagorn2023,
  author = {Dagorn, Pascale Gluais and Buchholz, Bjoern and Kraus, Andre and Batchuluun, Battsetseg and Bange, Hester and Blockken, Laura and Steinberg, Gregory R and Moller, David E and Hallakou-Bozec, Sophie},
  title = {A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease},
  journal = {Kidney International},
  year = {2023},
  volume = {103},
  number = {5},
  pages = {917--929},
  doi = {10.1016/j.kint.2023.01.026}
}
Kostenlos starten →